Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis

Annals of Epidemiology

Volumn 23, Issue 7, 2013, Pages 415-421

  Smits, Mark M ^a,b   Woudstra, Pier ^a,b   Utzschneider, Kristina M ^a,b   Tong, Jenny ^a,b   Gerchman, Fernando ^a,b   Faulenbach, Mirjam ^a,b   Carr, Darcy B ^b   Aston Mourney, Kathryn ^a,b   Chait, Alan ^b   Knopp, Robert H ^b,c   Meigs, James B ^d   Boyko, Edward J ^a   Kahn, Steven E ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adipokines; Cytokines; Factor analysis; Inflammatory proteins; Insulin sensitivity; Metabolic syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; SERUM AMYLOID A; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; FACTORIAL ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879462144     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2013.03.001     Document Type: Article

References (44)

1. Shen B.J., Todaro J.F., Niaura R., McCaffery J.M., Zhang J., Spiro A., et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003, 157(8):701-711.
2. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. JAm Coll Cardiol 2007, 49(4):403-414.
3. Lorenzo C., Okoloise M., Williams K., Stern M.P., Haffner S.M. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003, 26(11):3153-3159.
4. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28(9):2289-2304.
5. Ferguson T.F., Funkhouser E., Roseman J. Factor analysis of metabolic syndrome components in the Coronary Artery Risk Development in Young Adults (CARDIA) study: examination of factors by race-sex groups and across time. Ann Epidemiol 2010, 20(3):194-200.
6. Pladevall M., Singal B., Williams L.K., Brotons C., Guyer H., Sadurni J., et al. Asingle factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care 2006, 29(1):113-122.
7. Donahue R.P., Bean J.A., Donahue R.D., Goldberg R.B., Prineas R.J. Does insulin resistance unite the separate components of the insulin resistance syndrome? Evidence from the Miami Community Health Study. Arterioscler Thromb Vasc Biol 1997, 17(11):2413-2417.
8. Tong J., Boyko E.J., Utzschneider K.M., McNeely M.J., Hayashi T., Carr D.B., et al. Intra-abdominal fat accumulation predicts the development of the metabolicsyndrome in non-diabetic Japanese-Americans. Diabetologia 2007, 50(6):1156-1160.
9. Arner P. Insulin resistance in type 2 diabetes: role of the adipokines. Curr Mol Med 2005, 5(3):333-339.
10. Gil-Campos M., Canete R.R., Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004, 23(5):963-974.
11. Vettor R., Milan G., Rossato M., Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005, 22(Suppl 2):3-10.
12. Yudkin J.S., Juhan-Vague I., Hawe E., Humphries S.E., Di Minno G., Margaglione M., et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004, 53(7):852-857.
13. Babyak M.A., Green S.B. Confirmatory factor analysis: an introduction for psychosomatic medicine researchers. Psychosom Med 2010, 72(6):587-597.
14. Knopp R.H., Retzlaff B., Fish B., Walden C., Wallick S., Anderson M., et al. Effects of insulin resistance and obesity on lipoproteins and sensitivity to egg feeding. Arterioscler Thromb Vasc Biol 2003, 23(8):1437-1443.
15. Tannock L.R., O'Brien K.D., Knopp R.H., Retzlaff B., Fish B., Wener M.H., et al. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 2005, 111(23):3058-3062.
16. Beard J.C., Bergman R.N., Ward W.K., Porte D. The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. Diabetes 1986, 35(3):362-369.
17. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
18. Mueller R.O., Hancock G.R. Best practices in structural equation modeling. Best practices in quantitative methods 2007, 488-508. Sage, Thousand Oaks (CA). J.W. Osborne (Ed.).
19. Thompson B. Exploratory and confirmatory factor analysis 2004, American Psychological Association, Washington (DC).
20. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37(12):1595-1607.
21. Martinez-Vizcaino V., Martinez M.S., Aguilar F.S., Martinez S.S., Gutierrez R.F., Lopez M.S., et al. Validity of a single-factor model underlying the metabolic syndrome in children: a confirmatory factor analysis. Diabetes Care 2010, 33(6):1370-1372.
22. Brown T.A. Confirmatory Factor Analysis for Applied Research 2006, The Guilford Press, New York.
23. Hooper D., Coughlan J., Mullen M.R. Structural equation modelling: guidelines for determining model fit. Electronic Journal of Business Research Methods 2008, 6(1):53-60.
24. Newsom J. Some clarifications and recommendations on fit indices [accessed 30.11.11]. http://www.upa.pdx.edu/IOA/newsom/semclass/.
25. Tanaka J.S. Multifaceted conceptions of fit in structural equation models. Testing structural equation models 1993, Sage, Newbury Park (CA). K.A. Bollen, J.S. Long (Eds.).
26. Devaraj S., Singh U., Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009, 20(3):182-189.
27. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999, 19(4):972-978.
28. Alessi M.C., Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006, 26(10):2200-2207.
29. Juhan-Vague I., Alessi M.C., Mavri A., Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. JThromb Haemost 2003, 1(7):1575-1579.
30. Rega G., Kaun C., Weiss T.W., Demyanets S., Zorn G., Kastl S.P., et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005, 111(15):1938-1945.
31. Bastelica D., Morange P., Berthet B., Borghi H., Lacroix O., Grino M., et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002, 22(1):173-178.
32. Alessi M.C., Juhan-Vague I., Kooistra T., Declerck P.J., Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988, 60(3):491-494.
33. Nilsson L., Banfi C., Diczfalusy U., Tremoli E., Hamsten A., Eriksson P. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998, 18(11):1679-1685.
34. Nilsson L., Gafvels M., Musakka L., Ensler K., Strickland D.K., Angelin B., et al. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. JLipid Res 1999, 40(5):913-919.
35. Crandall D.L., Quinet E.M., El A.S., Hreha A.L., Leik C.E., Savio D.A., et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006, 26(10):2209-2215.
36. Ma L.J., Mao S.L., Taylor K.L., Kanjanabuch T., Guan Y., Zhang Y., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004, 53(2):336-346.
37. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. NEngl J Med 2000, 342(24):1792-1801.
38. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98(21):2241-2247.
39. Festa A., D'Agostino R., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51(4):1131-1137.
40. Cnop M., Havel P.J., Utzschneider K.M., Carr D.B., Sinha M.K., Boyko E.J., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003, 46(4):459-469.
41. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter?. Circulation 2007, 115(13):1806-1810.
42. Boronat M., Saavedra P., Varillas V.F., Novoa F.J. Use of confirmatory factor analysis for the identification of new components of the metabolic syndrome: the role of plasminogen activator inhibitor-1 and Haemoglobin A1c. Nutr Metab Cardiovasc Dis 2009, 19(4):271-276.
43. Marsland A.L., McCaffery J.M., Muldoon M.F., Manuck S.B. Systemic inflammation and the metabolic syndrome among middle-aged community volunteers. Metabolism 2010, 59(12):1801-1808.
44. Mundfrom D.J., Shaw D.G., Ke T.L. Minimum sample size recommendations for conducting factor analyses. Int J Test 2005, 5(2):159-168.